LENZ Therapeutics Inc
LENZ28.571USD
-1.389-4.63%
交易中 （美东）报价延迟15分钟
814.29M总市值
亏损市盈率 TTM
关于 LENZ Therapeutics Inc 公司
LENZ Therapeutics, Inc. 是一家处于临床后期的生物制药公司。该公司专注于开发首款基于乙酰克利定的眼药水，以改善被诊断为老花眼的患者的视力。其候选产品 LNZ100 和 LNZ101 是不含防腐剂的一次性眼药水，每日使用一次，分别含有乙酰克利定和乙酰克利定加布林莫尼定。LNZ100 和 LNZ101 正在注册授权 III 期 CLARITY 试验中进行临床评估，作为治疗老花眼的潜在疗法，老花眼影响着全球约 18 亿人和美国 1.28 亿人。
公司简介
公司代码LENZ
公司名称LENZ Therapeutics Inc
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
员工数量42
证券类型Ordinary Share
年结日Jun 25
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
国家- -
邮编- -
电话- -
网址- -
公司代码LENZ
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
公司高管
名称
名称/职务
职务
持股
持股变动
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
James Mccollum
James Mccollum
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
名称
名称/职务
职务
持股
持股变动
Marc Odrich
Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Shawn Olsson
Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
持股股东
持股股东
占比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
12.15%
Ridgeback Capital Management, L.P.
6.84%
Point72 Asset Management, L.P.
6.60%
Other
47.09%
股东类型
持股股东
占比
Venture Capital
41.87%
Hedge Fund
24.75%
Investment Advisor
21.00%
Investment Advisor/Hedge Fund
11.47%
Individual Investor
2.76%
Research Firm
0.79%
Bank and Trust
0.13%
Pension Fund
0.05%
Insurance Company
0.02%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
244
29.26M
103.53%
-770.18K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
2023Q1
205
7.41M
89.08%
-2.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
4.18M
14.85%
--
--
May 07, 2025
Alpha Wave Global, LP
3.61M
12.83%
--
--
Apr 14, 2025
Versant Ventures
3.66M
12.99%
-884.80K
-19.48%
Jun 27, 2025
Ridgeback Capital Management, L.P.
1.95M
6.93%
--
--
Apr 14, 2025
Point72 Asset Management, L.P.
1.88M
6.69%
+1.03M
+120.91%
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.42M
5.04%
-92.10K
-6.09%
Apr 14, 2025
The Vanguard Group, Inc.
1.20M
4.25%
+21.02K
+1.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.05M
3.73%
-14.66K
-1.38%
Mar 31, 2025
72 Investment Holdings, LLC
1.02M
3.62%
--
--
Mar 31, 2025
Sectoral Asset Management Inc.
977.25K
3.47%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Harbor Health Care ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P Pharmaceuticals ETF
0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.59%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
查看更多
Harbor Health Care ETF
占比0.91%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.89%
SPDR S&P Pharmaceuticals ETF
占比0.83%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.59%
iShares Micro-Cap ETF
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
iShares Biotechnology ETF
占比0.07%
Avantis US Small Cap Equity ETF
占比0.05%
Vanguard US Momentum Factor ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
公告日期
类型
比率
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
Mar 19, 2024
Merger
7<1
